The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Open accessPublished version of a preprint
Abstract
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ligation of PD-1 with its ligands programmed death-ligand 1 or 2 (PD-L1 or PD-L2) induces tyrosine phosphorylation of the PD-1 cytoplasmic domain by phosphorylating kinase Lck and subsequent recruitment of cytosolic tyrosine phosphatase SHP-2 and PD-1-associated SHP-2 preferentially dephosphorylates CD28 and suppresses CD28 costimulatory signaling leading to restrained effector T cell function (49”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overcoming such checkpoints through the use of therapeutic antibodies targeting the CTLA-4, PD-1, or PD-L1 cell-surface receptors was shown to be instrumental in promoting anti-tumor T cell responses in mice and in cancer patients”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Hui et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“SHP2 also has effects on parallel pathways (e.g., JAK/STAT signaling) and is implicated as an effector of inhibitory signaling by PD-1 and some other immune checkpoint receptors (Hui et al., 2017; Peled et al., 2018; Yokosuka et al., 2012).”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Hui et al., 2017
In the citing paper
“Among these, CD28 has recently been found to be the primary target (45).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [45]
In the citing paper
“The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-γ response likely reflected the need of CD28 to rescue exhausted CD8+ T cells, and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hui et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,410
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Advanced methods of microscope control using μManager software
Edelstein, A., Tsuchida, M. A., Amodaj, N., Pinkard, H., Vale, R. D., & Stuurman, N. (2014) · Journal of Biological Methods · doi:10.14440/jbm.2014.36 · Cited by 1,927
Self-citationButte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Zhang, W., Sloan‐Lancaster, J., Kitchen, J., Trible, R. P., & Samelson, L. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80901-0 · Cited by 1,271
Phase separation of signaling molecules promotes T cell receptor signal transduction
Su, X., Ditlev, J. A., Hui, E., Xing, W., Banjade, S., Okrut, J., King, D., Taunton, J., Rosen, M. K., & Vale, R. D. (2016) · Science · doi:10.1126/science.aad9964 · Cited by 1,260
Self-citationChemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,220
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Crystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe‐Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 997
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 873
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
PI3K in lymphocyte development, differentiation and activation
Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1056 · Cited by 824
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · cited 2×
“PD-1 has been shown to co-immunoprecipitate with tyrosine phosphatases Shp2, Shp1, and the Lck-inhibiting kinase Csk from cell lysates (20), and contains a structural motif that might recruit the lipid phosphatase SHIP-1 (27).”
BackgroundCD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
He, R., Hou, S., Liu, C., Zhang, A.-L., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X.-X., et al. (2016) · Nature · doi:10.1038/nature19317 · Cited by 643
Regulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4
Marengère, L. E. M., Waterhouse, P., Duncan, G. S., Mittrücker, H.-W., Feng, G.-S., & Mak, T. W. (1996) · Science · doi:10.1126/science.272.5265.1170 · Cited by 551
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomão, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm0902-1039c · Cited by 545
Force Microscopy of Nonadherent Cells: A Comparison of Leukemia Cell Deformability
Rosenbluth, M. J., Lam, W. A., & Fletcher, D. A. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.067496 · Cited by 535
TCR–peptide–MHC interactions in situ show accelerated kinetics and increased affinity
Huppa, J. B., Axmann, M., Moertelmaier, M., Lillemeier, B. F., Newell, E. W., Brameshuber, M. O., Klein, L. O., Schütz, G. J., & Davis, M. M. (2010) · Nature · doi:10.1038/nature08746 · Cited by 516
Evidence for the T3-associated 90K heterodimer as the T-cell antigen receptor
Meuer, S. C., Acuto, O., Hussey, R. E., Hodgdon, J. C., Fitzgerald, K. A., Schlossman, S. F., & Reinherz, E. L. (1983) · Nature · doi:10.1038/303808a0 · Cited by 465
Modeling T Cell Antigen Discrimination Based on Feedback Control of Digital ERK Responses
Altan-Bonnet, G. Y., & Germain, R. N. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030356 · Cited by 463
NFATc1 Regulates PD-1 Expression upon T Cell Activation
Oestreich, K. J., Yoon, H., Ahmed, R., & Boss, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4832 · Cited by 416
Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling
Pagès, F., Ragueneau, M., Rottapel, R. K., Truneh, A., Nunès, J. A., Imbert, J., & Olive, D. (1994) · Nature · doi:10.1038/369327a0 · Cited by 399
Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse
Choudhuri, K., Llodrá, J., Roth, E. W., Tsai, J., Gordo, S., Wucherpfennig, K. W., Kam, L. C., Stokes, D. L., & Dustin, M. L. (2014) · Nature · doi:10.1038/nature12951 · Cited by 397
ZAP-70: an essential kinase in T-cell signaling
Wang, H., Kadlecek, T. A., Au-Yeung, B. B., Goodfellow, H. E. S., Hsu, L. Y., Freedman, T. S., & Weiss, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002279 · Cited by 395
Switching Signals On or Off by Receptor Dimerization
Weiss, A., & Schlessinger, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81469-5 · Cited by 355
Yokosuka, T., Kobayashi, W., Sakata-Sogawa, K., Takamatsu, M., Hashimoto, A. S., Dustin, M. L., Tokunaga, M., & Saito, T. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.011 · Cited by 320
Bergman, M., Mustelin, T., Oetken, C., Partanen, J. M., Flint, N. A., Amrein, K. E., Autero, M., Burn, P., & Alitalo, K. K. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05361.x · Cited by 319
Human Influence on the Atmospheric Vertical Temperature Structure: Detection and Observations
Tett, S. F. B., Mitchell, J. F. B., Parker, D. E., & Allen, M. R. (1996) · Science · doi:10.1126/science.274.5290.1170 · Cited by 294
Bennett, F., Luxenberg, D. P., Ling, V., Wang, I., Marquette, K., Lowe, D., Khan, N., Veldman, G. M., Jacobs, K. A., Valge-Archer, V., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 291
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
Zinselmeyer, B. H., Heydari, S., Sacristán, C., Nayak, D., Cammer, M., Herz, J., Cheng, X., Davis, S. J., Dustin, M. L., & McGavern, D. B. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121416 · Cited by 271
Crystal Structure of Human Protein-tyrosine Phosphatase SHP-1
Yang, J. P., Liu, L., He, D., Song, X., Liang, X., Zhao, Z. J., & Zhou, G. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210430200 · Cited by 173
Direct single molecule measurement of TCR triggering by agonist pMHC in living primary T cells
O’Donoghue, G. P., Pielak, R. M., Smoligovets, A. A., Lin, J. J., & Groves, J. T. (2013) · eLife · doi:10.7554/elife.00778 · Cited by 166
Analysis of High Accuracy, Quantitative Proteomics Data in the MaxQB Database
Schaab, C., Geiger, T., Stoehr, G., Cox, J., & Mann, M. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014068 · Cited by 164
In vitro membrane reconstitution of the T-cell receptor proximal signaling network
Hui, E., & Vale, R. D. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2762 · Cited by 144
Self-citationThe reverse stop-signal model for CTLA4 function
Rudd, C. E. (2008) · Nature reviews. Immunology · doi:10.1038/nri2253 · Cited by 142
Schodin, B. A., Tsomides, T. J., & Kranz, D. M. (1996) · Immunity · doi:10.1016/s1074-7613(00)80490-2 · Cited by 108
Zikherman, J., Jenne, C. N., Watson, S. R., Doan, K., Raschke, W. C., Goodnow, C. C., & Weiss, A. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.006 · Cited by 90
Tian, R., Wang, H., Gish, G. D., Petsalaki, E., Pasculescu, A., Shi, Y., Mollenauer, M. N., Bagshaw, R. D., Yosef, N., Hunter, T. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503286112 · Cited by 78
Olszowy, M. W., Leuchtmann, P. L., Veillette, A., & Shaw, A. S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.9.4236 · Cited by 73
Structural Engineering of pMHC Reagents for T Cell Vaccines and Diagnostics
Mitaksov, V., Truscott, S. M., Lybarger, L. P., Connolly, J. M., Hansen, T. H., & Fremont, D. H. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.07.010 · Cited by 59
Mkrtichyan, M., Najjar, Y. G., Raulfs, E. C., Liu, L. L., Langerman, S., Guittard, G. C., Ozbun, L. L., & Khleif, S. N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103085 · Cited by 46
Zang, X., Loke, P., Kim, J., Wojnoonski, K., Kusdra, L., & Allison, J. P. (2006) · Genomics · doi:10.1016/j.ygeno.2006.08.012 · Cited by 13
Self-citationChung, Y., Sinzinger, M. D., Bovée‐Geurts, P. H. M., Krause, M., Dinkla, S., Joosten, I., Koopman, W. J. H., Adjobo-Hermans, M. J. W., & Brock, R. E. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2011.09.058 · Cited by 7
Flagged first, then by citations
Cited by
Sorted by citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Self-citationRegulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,248
Metadata
- Authors
- Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., & Vale, R. D.
- Affiliations
- Howard Hughes Medical Institute (US)
- Genentech (US)
- University of Chicago (US)
- Corresponding author
- Mellman, Ira
- Vale, Ronald D.
- ORCID
- Venue
- Science
- Published
- 2017-03-31
- Volume
- 355
- Issue
- 6332
- Pages
- 1428-1433
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286077
- OpenAlex
- W2592133876
- Cited by
- 1,689
- References
- 68
- Citations by year
- 2026: 121 · 2025: 158 · 2024: 201 · 2023: 203 · 2022: 193 · 2021: 218 · 2020: 224 · 2019: 159 · 2018: 143 · 2017: 63
- FWCI
- 70.99
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Chicago Biomedical Consortium
- NIH (R21AI120010, R00AI106941)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, CD28, PD-L1, T cell costimulation, T cell receptor signaling, SHP2, receptor dephosphorylation, T cell activation, anti-PD-1 therapy, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Lymphocyte Activation, Mice, Inbred C57BL, Neoplasms, Phosphorylation, T-Lymphocytes, CD28 Antigens, Jurkat Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
